Recombinant Proteins Market Trends, Business Overview, Industry Growth and Forecast to 2028 

The recombinant protein market was valued at USD 125.8 billion in 2020, and it is expected to register a CAGR of 11.2% over the forecast period, 2021-2026. The growth of the recombinant protein market is attributed to the increased expenditure on R&D, the growing prevalence of chronic diseases, rising inclination toward biologics and biosimilars, and advanced recombinant products.

Scope of the Report

The research study analyzes the Global Recombinant Proteins Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Market – Segmentation

By Type of Product

• Antibodies
• Hormones
• Growth Factors 
• Cytokines
• Others

 By Application

• Therapeutic Use
• Research Application
• Biotechnology Industry

 By End User

• Biotechnology Companies
• Research Institutes
• Others

Company Profile

• Abcam PLC, Amgen Inc.
•  Bio-Rad Laboratories Inc.
•  Eli Lilly and Company
•  Enzo Biochem, Inc (Enzo Life Sciences Inc.)
•  Merck KGaA
•  Novo Nordisk AS
•  ProSpec-Tany TechnoGene Ltd
•  Sanofi SA
• Thermo Fisher Scientific Inc.

Recent Developments

• Market Overview and growth analysis
• Import and Export Overview
• Volume Analysis
• Current Market Trends and Future Outlook
• Market Opportunistic and Attractive Investment Segment

Geographic Coverage

• North America Market Size and/or Volume
• Latin America Market Size and/or Volume
• Europe Market Size and/or Volume
• Asia-Pacific Market Size and/or Volume
• Rest of the world Market Size and/or Volume